Natco Pharma net profit declines 43 percent to Rs 53 crore in Q4

Published On 2021-06-20 05:00 GMT   |   Update On 2021-06-20 05:00 GMT
Advertisement

New Delhi: Drug firm Natco Pharma on Thursday said its consolidated net profit declined by 43 per cent to Rs 53 crore for the fourth quarter ended March 31, 2021.

The Hyderabad-based company had posted a net profit of Rs 93 crore for the January-March quarter of 2019-20 fiscal.

Total income during the fourth quarter stood at Rs 360 crore, down from Rs 477 crore in the fourth quarter of the financial year 2019-20, the drugmaker said in a regulatory filing.

Advertisement

For the entire 2020-21 fiscal, the company posted a consolidated net profit of Rs 442 crore as compared with Rs 458 crore in 2019-20.

Total income increased to Rs 2,156 crore in the last fiscal from Rs 2,022 crore in the financial year 2019-20.

Read also: Natco Pharma marketing partner gets USFDA approval for Everolimus tablets

"In spite of the significant negative impact of the pandemic on the base business, the company was able to sustain its revenue during the year," the drug firm noted.

The company expects strong growth during the current financial year due to multiple high-value product launches in the US, rebound in domestic India business with new products, and contribution from the Crop Health division, it added.

Read also: Natco Pharma marketing partner gets USFDA nod for Carfilzomib Vials ANDA



Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News